Table 1 Demographic, clinical, and pathological characteristics of the 208 patients
From: Clinico-pathological factors predicting pathological response in early triple-negative breast cancer
Characteristic | According to pCR | |||||
|---|---|---|---|---|---|---|
N = | no pCR, N = 631 | pCR, N = 1451 | p-val2 | OR | 95% CI | |
Age—median (IQR) | 208 | 48 (39, 56) | 49 (42, 56) | 0.5 | 1.01 | 0.98, 1.04 |
ECOG PS | 202 | 0.6 | ||||
0 | 58 (29%) | 139 (71%) | – | – | ||
1 | 2 (40%) | 3 (60%) | 0.63 | 0.10, 4.84 | ||
Missing | 6 | |||||
Menopausal status | 207 | >0.9 | ||||
Postmenopausal | 26 (30%) | 60 (70%) | – | – | ||
Premenopausal | 36 (30%) | 85 (70%) | 1.02 | 0.56, 1.87 | ||
Missing | 1 | |||||
BMI—median (IQR) | 208 | 25 (23, 32) | 25 (22, 29) | 0.15 | 1.00 | 1.00, 1.00 |
Germline mutation | 207 | 0.016 | ||||
No | 61 (35%) | 114 (65%) | – | – | ||
BRCA1 | 2 (8.7%) | 21 (91%) | 8.03 | 2.32, 50.7 | ||
BRCA2 | 0 (0%) | 5 (100%) | ||||
PALB2 | 0 (0%) | 1 (100%) | ||||
RAD51C | 0 (0%) | 3 (100%) | ||||
Unknown | 1 | |||||
Primary tumor | 208 | <0.001 | ||||
T3–T4 | 26 (48%) | 28 (52%) | – | – | ||
T1–T2 | 37 (24%) | 117 (76%) | 2.94 | 1.53, 5.65 | ||
Nodal involvement | 208 | 0.3 | ||||
N0 | 22 (26%) | 62 (74%) | – | – | ||
N+ | 41 (33%) | 83 (67%) | 0.72 | 0.38, 1.32 | ||
Stage | 208 | 0.017 | ||||
II | 38 (26%) | 111 (74%) | – | – | ||
III | 25 (42%) | 34 (58%) | 0.47 | 0.25, 0.88 | ||
Histological subtype | 208 | 0.001 | ||||
NST | 53 (28%) | 138 (72%) | – | |||
Lobular | 3 (100%) | 0 (0%) | ||||
Apocrine carcinoma | 4 (100%) | 0 (0%) | ||||
Metaplastic carcinoma | 1 (20%) | 4 (80%) | ||||
Others | 2 (40%) | 3 (60%) | ||||
DCIS on pre-treatment biopsy | 192 | 0.009 | ||||
Yes | 16 (47%) | 18 (53%) | – | – | ||
No | 39 (25%) | 119 (75%) | 2.71 | 1.26, 5.85 | ||
Missing | 16 | |||||
DCIS residual after surgery | 206 | <0.001 | ||||
Yes | 22 (73%) | 8 (27%) | – | – | ||
No | 39 (22%) | 136 (78%) | 9.66 | 4.14, 24.7 | ||
Missing | 2 | |||||
Grade | 208 | 0.030 | ||||
II | 13 (48%) | 14 (52%) | – | – | ||
III | 50 (28%) | 131 (72%) | 2.43 | 1.06, 5.57 | ||
ER | 208 | 0.6 | ||||
<1% | 55 (31%) | 123 (69%) | – | – | ||
1–<10% | 8 (27%) | 22 (73%) | 1.23 | 0.53, 3.10 | ||
PR | 208 | >0.9 | ||||
<1% | 61 (30%) | 141 (70%) | – | – | ||
1–<10% | 2 (33%) | 4 (67%) | 0.87 | 0.16, 6.36 | ||
HER2 | 208 | 0.8 | ||||
0 | 29 (29%) | 70 (71%) | – | – | ||
Low (1+, 2+, FISH−) | 34 (31%) | 75 (69%) | 0.91 | 0.50, 1.65 | ||
AR—median (IQR) | 156 | 1 (0, 20) | 3 (0, 15) | >0.9 | 0.99 | 0.98, 1.01 |
AR positivity (≥10%) | 156 | 0.8 | ||||
Negative | 32 (29%) | 77 (71%) | – | – | ||
Positive | 13 (28%) | 34 (72%) | 1.09 | 0.52, 2.38 | ||
Missing | 52 | |||||
Ki67 (%) | 208 | 60 (30, 80) | 70 (50, 80) | <0.001 | 1.03 | 1.01, 1.04 |
Ki67 positivity | 208 | <0.001 | ||||
<30% | 15 (68%) | 7 (32%) | – | – | ||
≥30% | 48 (26%) | 138 (74%) | 6.16 | 2.45, 17.0 | ||
Non-centralized TILs—median (IQR) | 197 | 20 (5, 40) | 20 (10, 40) | 0.4 | 1.00 | 0.99, 1.02 |
Non-centralized TILs (%) | 197 | 0.3 | ||||
<30% | 41 (34%) | 81 (66%) | – | – | ||
30–50% | 5 (18%) | 23 (82%) | 2.33 | 0.88, 7.33 | ||
>50% | 14 (30%) | 33 (70%) | 1.19 | 0.58, 2.53 | ||
Missing | 11 | |||||
Centralized TILs—median (IQR) | 182 | 15 (5, 25) | 25 (10, 50) | <0.001 | 1.04 | 1.02, 1.06 |
Centralized TILs (%) | 182 | 0.002 | ||||
<30% | 44 (41%) | 63 (59%) | – | – | ||
30–50% | 8 (24%) | 25 (76%) | 2.18 | 0.93, 5.58 | ||
>50% | 5 (12%) | 37 (88%) | 5.17 | 2.03, 15.9 | ||
Missing | 26 | |||||
PD-L1 CPS—median (IQR) | 150 | 12 (5, 15) | 15 (5, 30) | 0.008 | 1.03 | 1.01, 1.06 |
PD-L1 CPS (%) | 150 | 0.023 | ||||
<10 | 18 (38%) | 30 (63%) | – | – | ||
10–19 | 15 (32%) | 32 (68%) | 1.28 | 0.55, 3.01 | ||
≥20 | 8 (15%) | 47 (85%) | 3.53 | 1.40, 9.55 | ||
Missing | 58 | |||||
